| RTX |
Report |
Q2 2026 adjusted EPS |
BEAT |
pred ~$1.74 vs. cons $1.66 |
MEDIUM |
| RTX |
Report |
Q2 2026 adjusted sales |
IN-LINE |
pred ~$23.08B vs. cons $22.87B |
MEDIUM |
| RTX |
Report |
Q2 2026 Raytheon adjusted operating profit |
BEAT |
pred ~$925M vs. cons $910M |
LOW |
| RTX |
Guide |
FY2026 adjusted EPS guidance midpoint |
BETTER |
guide ~$6.95 vs. cons $6.94 (FY2026) |
MEDIUM |
| RTX |
Guide |
FY2026 adjusted sales guidance midpoint |
LOWER |
guide ~$94.00B vs. cons $94.08B (FY2026) |
MEDIUM |
| RTX |
Guide |
FY2026 free cash flow guidance midpoint |
UNCHANGED |
guide ~$8.50B vs. cons $8.60B (FY2026) |
MEDIUM |
| RTX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.6% |
— |
LOW |
| RTX |
Return |
5-day cumulative residual |
+0.5% (FADE) |
Day-5 residual ~+0.5% vs. day-1 residual ~+1.6%: the EPS beat and Raytheon execution support the initial move, but a FY2026 sales guide near ~$94.00B versus ~$94.08B consensus and unchanged ~$8.50B free-cash-flow guidance versus ~$8.60B consensus limit out-period estimate revisions. |
LOW |